Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹6.82
-₹0.12(-1.73%)
At close: 4:00 PM EDT
₹6.82
-₹0.12(-1.73%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹14.14
Previous CloseN/A
Volume22.89K
Average Volume (3M)5.92K
Market Cap
₹345.70M
Enterprise Value₹648.10
Total Cash (Recent Filing)₹6.97M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding50,101,240
10 Day Avg. Volume7,213
30 Day Avg. Volume5,920
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow leverage provides some financial flexibility and reduces immediate balance-sheet strain. This may help LASA fund operations or restructuring without the same debt burden faced by more highly leveraged peers.
API And Intermediate Product BreadthParticipation across APIs, intermediates and therapeutic categories can diversify demand beyond a single molecule or end market. Domestic and export exposure also provides a broader base for rebuilding volumes over time.
Demonstrated Historical Cash GenerationEarlier periods of positive and strong operating cash flow show that the business has previously converted operations into cash. That historical capability offers a foundation for recovery, although recent execution has not sustained it.
Bears Say
Severe Revenue ContractionThe scale and persistence of the revenue decline indicate more than a temporary fluctuation, raising concerns about customer retention, capacity utilization and competitive position. Lower volumes can also make manufacturing costs harder to absorb.
Deeply Negative ProfitabilitySustained losses and negative gross margin point to fundamental pricing, cost or production problems rather than ordinary earnings volatility. Continued weakness could erode capital, restrict investment and make a durable turnaround more difficult.
Weak Cash Generation And ReturnsNegative operating cash flow limits internally funded investment and may increase reliance on existing balance-sheet resources. Combined with sharply negative returns on equity, this signals inefficient capital use and ongoing risk of value erosion.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹14.14 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹345.70M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 72 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.714 earnings per share for the quarter.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.714 in its last earnings report. Following the earnings report the stock price went up 1.743%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―